首页 > 最新文献

Mediastinum (Hong Kong, China)最新文献

英文 中文
Robotic resection of anterior mediastinal masses >10 cm: a case series. 机器人切除>10 cm前纵隔肿物1例。
Pub Date : 2023-01-01 DOI: 10.21037/med-22-41
Obada Alqudah, Rhusmi Purmessur, John Hogan, Haisam Saad, Joana Fuentes-Warr, Jonathon Francis, Santosh Thandayuthapani, Vasileios Kouritas

Background: Robot-assisted thoracic surgery (RATS) for intrathoracic pathology and especially for mediastinal mass resection has been increasingly accepted as an alternative method to open sternotomy and video-assisted thoracic surgery (VATS). However, the utilization of this approach for complex and advanced in size cases needs more clinical evidence. We are presenting a series of 4 patients who had resection of >10 cm mediastinal masses via RATS.

Cases description: The mean age was 76.25±10.3 years and 3 were males (75%). All masses were positron emission tomography (PET) positive, and 1 patient had positive Acetyl-cholinesterase antibodies and myasthenia gravis (MG). All patients underwent RATS resection via DaVinci® X system. The dissections were conducted with spatula and/or Maryland bipolar forceps. In 2 cases, the resection was done with bilateral docking, and in 1 case, a drain was not inserted at the end. In 1 patient, pericardial resection was necessitated. All masses were thymomas with 1 dimension measured >10 cm on pathology. All patients were discharged on day 1 or 2 postoperatively with uneventful recoveries. There was no in-hospital, 30- or 90-day mortality. All patients were found to be without issues on follow-up.

Conclusions: This report shows that RATS is safe and can be offered in the management of >10 cm anterior mediastinal masses. The previous size limit of the tumor for minimally invasive and especially RATS approach of 5 cm should be challenged.

背景:机器人辅助胸外科手术(RATS)用于胸内病理,特别是纵隔肿块切除术已越来越多地被接受为开放式胸骨切开和视频辅助胸外科手术(VATS)的替代方法。然而,这种方法在复杂和先进的情况下的应用需要更多的临床证据。我们报告了4例经大鼠造影(RATS)切除>10厘米纵隔肿块的患者。病例描述:平均年龄76.25±10.3岁,男性3例(75%)。所有肿块均为正电子发射断层扫描(PET)阳性,1例患者乙酰胆碱酯酶抗体阳性,重症肌无力(MG)。所有患者均通过达芬奇®X系统行大鼠切除术。使用刮刀和/或马里兰双极钳进行解剖。其中2例采用双侧对接切除,1例未在末端插入引流管。1例患者行心包切除术。所有肿块均为胸腺瘤,病理检查尺寸>10 cm。所有患者均于术后第1天或第2天出院,恢复正常。没有住院30天或90天的死亡率。随访发现所有患者均无问题。结论:RATS是安全的,可用于治疗>10 cm的前纵隔肿块。以往对于微创尤其是rat入路的肿瘤大小限制为5cm,应予挑战。
{"title":"Robotic resection of anterior mediastinal masses >10 cm: a case series.","authors":"Obada Alqudah,&nbsp;Rhusmi Purmessur,&nbsp;John Hogan,&nbsp;Haisam Saad,&nbsp;Joana Fuentes-Warr,&nbsp;Jonathon Francis,&nbsp;Santosh Thandayuthapani,&nbsp;Vasileios Kouritas","doi":"10.21037/med-22-41","DOIUrl":"https://doi.org/10.21037/med-22-41","url":null,"abstract":"<p><strong>Background: </strong>Robot-assisted thoracic surgery (RATS) for intrathoracic pathology and especially for mediastinal mass resection has been increasingly accepted as an alternative method to open sternotomy and video-assisted thoracic surgery (VATS). However, the utilization of this approach for complex and advanced in size cases needs more clinical evidence. We are presenting a series of 4 patients who had resection of >10 cm mediastinal masses via RATS.</p><p><strong>Cases description: </strong>The mean age was 76.25±10.3 years and 3 were males (75%). All masses were positron emission tomography (PET) positive, and 1 patient had positive Acetyl-cholinesterase antibodies and myasthenia gravis (MG). All patients underwent RATS resection via DaVinci<sup>®</sup> X system. The dissections were conducted with spatula and/or Maryland bipolar forceps. In 2 cases, the resection was done with bilateral docking, and in 1 case, a drain was not inserted at the end. In 1 patient, pericardial resection was necessitated. All masses were thymomas with 1 dimension measured >10 cm on pathology. All patients were discharged on day 1 or 2 postoperatively with uneventful recoveries. There was no in-hospital, 30- or 90-day mortality. All patients were found to be without issues on follow-up.</p><p><strong>Conclusions: </strong>This report shows that RATS is safe and can be offered in the management of >10 cm anterior mediastinal masses. The previous size limit of the tumor for minimally invasive and especially RATS approach of 5 cm should be challenged.</p>","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":"7 ","pages":"29"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/87/ab/med-07-29.PMC10493617.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10242971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Asymptomatic lipofibroadenoma in a 17-year-old male: a case report and literature review of a rare entity. 17岁男性无症状脂肪纤维腺瘤:一例罕见病例报告及文献复习。
Pub Date : 2023-01-01 DOI: 10.21037/med-22-32
Michael A den Bakker, Marijn A Vermeulen, Cornelis P van de Ven, Simone A J Ter Horst, Lennart Kester, Ronald R de Krijger

Background: The most common thymic tumours, thymomas, are derived from thymic epithelium and are generally low-grade neoplasm. Frankly malignant tumours, thymic carcinomas are rarer still. Exceedingly rare thymic tumours contain a mesenchymal tissue component such as fibrous connective tissue and/or mature fat. Lipofibroadenoma (LFA) is a very rare mixed epithelial-mesenchymal thymic tumour, included in the category of thymic epithelial tumors. LFA in addition to a mature adipocytic component, contains variable epithelial and mesenchymal tissue components. Owing to the presence of an epithelial component in LFA, this entity, in contrast to thymolipoma, is included in the World Health Organization (WHO) category of thymic epithelial neoplasm. Currently only 12 LFA cases have been described. The 12 previously reported cases all behaved in a benign fashion, although four cases were associated with a conventional type of thymoma. We here present a new, 13th, case of LFA.

Case description: The LFA was discovered incidentally in a previously healthy 17-year-old male after investigations for suspected pneumonia. On imaging a mass was discovered in the anterior mediastinum which was subsequently surgically removed. The resected tumour was extensively investigated, including the first instance of full molecular analysis of this rare entity and all available literature on LFA was sourced to provide a comprehensive overview. The histology of this LFA was similar to previously described cases. No gene mutations or rearrangements were identified. The patient made an uneventful recovery and after 13 months of follow-up remained well.

Conclusions: An additional, 13th case of LFA is presented. Based on the available literature it appears that LFA may be considered a benign composite thymic tumour, although the combination of an additional conventional thymoma component may warrant closer follow-up.

背景:最常见的胸腺肿瘤,胸腺瘤,起源于胸腺上皮,通常是低级别肿瘤。坦率地说,恶性肿瘤,胸腺癌更罕见。极为罕见的胸腺肿瘤含有间充质组织成分,如纤维结缔组织和/或成熟脂肪。脂纤维腺瘤是一种非常罕见的胸腺上皮-间充质混合性肿瘤,属于胸腺上皮性肿瘤。LFA除了含有成熟的脂肪细胞成分外,还含有可变的上皮和间充质组织成分。由于LFA中存在上皮成分,与胸腺脂肪瘤不同,该实体被列入世界卫生组织(WHO)的胸腺上皮肿瘤类别。目前仅报道了12例LFA病例。先前报道的12例病例均表现为良性,尽管有4例与传统类型的胸腺瘤相关。我们在此报告第13例LFA病例。病例描述:LFA是在一名先前健康的17岁男性疑似肺炎调查后偶然发现的。影像学发现前纵隔有肿块,随后手术切除。我们对切除的肿瘤进行了广泛的研究,包括首次对这种罕见的肿瘤进行了完整的分子分析,并收集了所有关于LFA的文献,以提供一个全面的概述。该LFA的组织学与先前描述的病例相似。没有发现基因突变或重排。患者顺利康复,随访13个月后病情保持良好。结论:本文报告了第13例LFA病例。根据现有文献,LFA可能被认为是一种良性的复合胸腺肿瘤,尽管合并了一种额外的常规胸腺瘤成分可能需要更密切的随访。
{"title":"Asymptomatic lipofibroadenoma in a 17-year-old male: a case report and literature review of a rare entity.","authors":"Michael A den Bakker,&nbsp;Marijn A Vermeulen,&nbsp;Cornelis P van de Ven,&nbsp;Simone A J Ter Horst,&nbsp;Lennart Kester,&nbsp;Ronald R de Krijger","doi":"10.21037/med-22-32","DOIUrl":"https://doi.org/10.21037/med-22-32","url":null,"abstract":"<p><strong>Background: </strong>The most common thymic tumours, thymomas, are derived from thymic epithelium and are generally low-grade neoplasm. Frankly malignant tumours, thymic carcinomas are rarer still. Exceedingly rare thymic tumours contain a mesenchymal tissue component such as fibrous connective tissue and/or mature fat. Lipofibroadenoma (LFA) is a very rare mixed epithelial-mesenchymal thymic tumour, included in the category of thymic epithelial tumors. LFA in addition to a mature adipocytic component, contains variable epithelial and mesenchymal tissue components. Owing to the presence of an epithelial component in LFA, this entity, in contrast to thymolipoma, is included in the World Health Organization (WHO) category of thymic epithelial neoplasm. Currently only 12 LFA cases have been described. The 12 previously reported cases all behaved in a benign fashion, although four cases were associated with a conventional type of thymoma. We here present a new, 13th, case of LFA.</p><p><strong>Case description: </strong>The LFA was discovered incidentally in a previously healthy 17-year-old male after investigations for suspected pneumonia. On imaging a mass was discovered in the anterior mediastinum which was subsequently surgically removed. The resected tumour was extensively investigated, including the first instance of full molecular analysis of this rare entity and all available literature on LFA was sourced to provide a comprehensive overview. The histology of this LFA was similar to previously described cases. No gene mutations or rearrangements were identified. The patient made an uneventful recovery and after 13 months of follow-up remained well.</p><p><strong>Conclusions: </strong>An additional, 13th case of LFA is presented. Based on the available literature it appears that LFA may be considered a benign composite thymic tumour, although the combination of an additional conventional thymoma component may warrant closer follow-up.</p>","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":"7 ","pages":"19"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f1/f1/med-07-19.PMC10226891.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9620833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Review of the clinical outcomes of therapeutic bronchoscopy for central airway obstruction. 支气管镜治疗中央气道阻塞的临床效果综述。
Pub Date : 2023-01-01 DOI: 10.21037/med-22-39
An Thi Nhat Ho, Archan Shah, Ala Eddin S Sagar

Central airway obstruction (CAO) is a debilitating condition with a significant impact on patient's quality of life and risk of hospitalization from respiratory failure. The causes of CAO can be both benign and malignant. Benign CAO may be idiopathic or secondary to other disease processes (infection, intubation, tracheostomy, etc.). Malignant central airway obstruction (MCAO) may occur in patients with primary lung malignancy as well as metastasis from other malignancies including renal cell, colon, and breast. In a cohort review, MCAO was found in up to 13% of patients with newly diagnosed lung cancer. The obstruction may occur either due to endoluminal disease, extrinsic compression, or a combination of both. Several bronchoscopic tools are available to manage such obstruction. Practice patterns and tools used to relieve CAO vary between institutions and may depend on physician preference, patient characteristics, emergency nature of the procedure, and nature of the obstruction. To quantify the effect and added value of such interventions, it is crucial to understand the clinical impact these interventions have on patients. The clinical impact of therapeutic bronchoscopy (TB) must then be weighed against the potential complications to justify its value. Early studies of TB for CAO included patients with both malignant and benign etiologies. The study population's heterogeneity makes it difficult to determine how TB affects clinical outcomes, as clinical outcomes are disease specific. The impact of TB for a MCAO may be different when compared to a benign CAO. Similarly, the clinical outcome of treating an idiopathic benign CAO may be different than that of a post tracheostomy airway obstruction. In this article, we will focus on the clinical outcomes of TB in MCAO. TB has been shown to have a clear impact on weaning from mechanical ventilation, dyspnea, health-related quality of life, survival and quality adjusted survival. The potential impact of TB on these outcomes should be weighed against the potential risk of complications. Understanding the factors associated with improved clinical outcomes will help physicians decide when and if TB is helpful. Future studies should focus on creating a decision analysis tool to further define decision thresholds.

中央气道阻塞(CAO)是一种衰弱性疾病,对患者的生活质量和因呼吸衰竭住院的风险有重大影响。曹操的病因有良性和恶性两种。良性曹操可能是特发性或继发于其他疾病过程(感染、插管、气管切开术等)。恶性中央气道阻塞(MCAO)可能发生在原发性肺恶性肿瘤患者以及其他恶性肿瘤的转移,包括肾细胞、结肠和乳腺。在一项队列回顾中,MCAO在高达13%的新诊断肺癌患者中被发现。梗阻的发生可能是由于腔内疾病、外部压迫或两者兼有。有几种支气管镜工具可用于治疗这种阻塞。不同机构用于缓解CAO的实践模式和工具各不相同,可能取决于医生的偏好、患者的特点、手术的紧急性质和梗阻的性质。为了量化这些干预措施的效果和附加价值,了解这些干预措施对患者的临床影响至关重要。治疗性支气管镜检查(TB)的临床效果必须与潜在的并发症进行权衡,以证明其价值。早期对曹操患者的结核病研究包括恶性和良性病因。研究人群的异质性使得很难确定结核病如何影响临床结果,因为临床结果是疾病特异性的。结核对MCAO的影响可能与良性CAO不同。同样,治疗特发性良性CAO的临床结果可能与气管切开术后气道阻塞的临床结果不同。在这篇文章中,我们将重点关注结核病在MCAO的临床结果。结核病已被证明对机械通气脱机、呼吸困难、健康相关生活质量、生存和质量调整生存有明显影响。应将结核病对这些结果的潜在影响与并发症的潜在风险进行权衡。了解与改善临床结果相关的因素将有助于医生决定结核病何时以及是否有帮助。未来的研究应侧重于创建决策分析工具,以进一步定义决策阈值。
{"title":"Review of the clinical outcomes of therapeutic bronchoscopy for central airway obstruction.","authors":"An Thi Nhat Ho,&nbsp;Archan Shah,&nbsp;Ala Eddin S Sagar","doi":"10.21037/med-22-39","DOIUrl":"https://doi.org/10.21037/med-22-39","url":null,"abstract":"<p><p>Central airway obstruction (CAO) is a debilitating condition with a significant impact on patient's quality of life and risk of hospitalization from respiratory failure. The causes of CAO can be both benign and malignant. Benign CAO may be idiopathic or secondary to other disease processes (infection, intubation, tracheostomy, etc.). Malignant central airway obstruction (MCAO) may occur in patients with primary lung malignancy as well as metastasis from other malignancies including renal cell, colon, and breast. In a cohort review, MCAO was found in up to 13% of patients with newly diagnosed lung cancer. The obstruction may occur either due to endoluminal disease, extrinsic compression, or a combination of both. Several bronchoscopic tools are available to manage such obstruction. Practice patterns and tools used to relieve CAO vary between institutions and may depend on physician preference, patient characteristics, emergency nature of the procedure, and nature of the obstruction. To quantify the effect and added value of such interventions, it is crucial to understand the clinical impact these interventions have on patients. The clinical impact of therapeutic bronchoscopy (TB) must then be weighed against the potential complications to justify its value. Early studies of TB for CAO included patients with both malignant and benign etiologies. The study population's heterogeneity makes it difficult to determine how TB affects clinical outcomes, as clinical outcomes are disease specific. The impact of TB for a MCAO may be different when compared to a benign CAO. Similarly, the clinical outcome of treating an idiopathic benign CAO may be different than that of a post tracheostomy airway obstruction. In this article, we will focus on the clinical outcomes of TB in MCAO. TB has been shown to have a clear impact on weaning from mechanical ventilation, dyspnea, health-related quality of life, survival and quality adjusted survival. The potential impact of TB on these outcomes should be weighed against the potential risk of complications. Understanding the factors associated with improved clinical outcomes will help physicians decide when and if TB is helpful. Future studies should focus on creating a decision analysis tool to further define decision thresholds.</p>","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":"7 ","pages":"17"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/01/eb/med-07-17.PMC10226892.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9620837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anatomy of mediastinal veins and nerves. 纵隔静脉和神经解剖。
Pub Date : 2023-01-01 DOI: 10.21037/med-20-65
Abby White, Ashley L Deeb

The mediastinum is the central compartment in the thoracic cavity that lies between the lungs. It extends from the thoracic inlet superiorly to the diaphragm inferiorly and sternum anteriorly to the vertebral column posteriorly. It is commonly divided into four compartments-superior, anterior, middle and posterior mediastinum. However, some have started to classify it into the more recent three compartments-anterior (prevascular), middle (visceral) and posterior (paravertebral). The mediastinum is of clinical significance because many vital structures, such as the heart, great vessels, esophagus, lymphatics, and trachea, lie within these compartments. Disease presentation can greatly vary depending on the structures involved, and the differential diagnosis can range widely. Therefore, knowledge of the anatomy and subdivisions of the mediastinum is vital for thoracic surgeons. Herein, we have provided a brief review of the mediastinal anatomy. Utilizing the four-compartment model, we detail the contents of each compartment of the mediastinum with special attention to its veins and nerves. There are also several venous junctions that are important for mediastinal surgery, such as the internal jugular-subclavian venous junction and the left-right brachiocephalic venous junction. We describe useful superficial landmarks, such as the sternocleidomastoid and manubrium, and how they relate to some of the key venous junctions.

纵隔是胸腔的中心隔室,位于两肺之间。它从胸入口处向上延伸,向下延伸到隔膜,向前延伸到胸骨,向后延伸到脊柱。它通常分为四个腔室——上纵隔、前纵隔、中纵隔和后纵隔。然而,一些人开始将其分为最近的三个腔室——前(血管前)、中(内脏)和后(椎旁)。纵隔具有重要的临床意义,因为许多重要结构,如心脏、大血管、食道、淋巴管和气管都位于这些隔室内。疾病的表现可以根据所涉及的结构而有很大的不同,鉴别诊断的范围也很广。因此,纵隔解剖和细分的知识是至关重要的胸外科医生。在此,我们提供了纵隔解剖的简要回顾。利用四室模型,我们详细介绍了纵隔每个室的内容物,特别注意其静脉和神经。也有几个静脉连接处对纵隔手术很重要,如颈内-锁骨下静脉连接处和左右头臂静脉连接处。我们描述有用的表面标志,如胸锁乳突肌和柄肌,以及它们与一些关键静脉连接点的关系。
{"title":"Anatomy of mediastinal veins and nerves.","authors":"Abby White,&nbsp;Ashley L Deeb","doi":"10.21037/med-20-65","DOIUrl":"https://doi.org/10.21037/med-20-65","url":null,"abstract":"<p><p>The mediastinum is the central compartment in the thoracic cavity that lies between the lungs. It extends from the thoracic inlet superiorly to the diaphragm inferiorly and sternum anteriorly to the vertebral column posteriorly. It is commonly divided into four compartments-superior, anterior, middle and posterior mediastinum. However, some have started to classify it into the more recent three compartments-anterior (prevascular), middle (visceral) and posterior (paravertebral). The mediastinum is of clinical significance because many vital structures, such as the heart, great vessels, esophagus, lymphatics, and trachea, lie within these compartments. Disease presentation can greatly vary depending on the structures involved, and the differential diagnosis can range widely. Therefore, knowledge of the anatomy and subdivisions of the mediastinum is vital for thoracic surgeons. Herein, we have provided a brief review of the mediastinal anatomy. Utilizing the four-compartment model, we detail the contents of each compartment of the mediastinum with special attention to its veins and nerves. There are also several venous junctions that are important for mediastinal surgery, such as the internal jugular-subclavian venous junction and the left-right brachiocephalic venous junction. We describe useful superficial landmarks, such as the sternocleidomastoid and manubrium, and how they relate to some of the key venous junctions.</p>","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":"7 ","pages":"14"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/cb/med-07-14.PMC10226887.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9620834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in thoracic surgery for thymic tumors: extended abstract. 胸腺肿瘤的胸外科手术进展:扩展摘要。
Pub Date : 2023-01-01 DOI: 10.21037/med-21-62
Jens C Rückert, Luyu Huang
{"title":"Advances in thoracic surgery for thymic tumors: extended abstract.","authors":"Jens C Rückert,&nbsp;Luyu Huang","doi":"10.21037/med-21-62","DOIUrl":"https://doi.org/10.21037/med-21-62","url":null,"abstract":"","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":"7 ","pages":"9"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4e/1c/med-07-9.PMC10011865.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9131147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multimodality imaging of mediastinal masses and mimics. 纵隔肿块和模拟的多模态成像。
Pub Date : 2023-01-01 DOI: 10.21037/med-22-53
John Matthew Archer, Jitesh Ahuja, Chad D Strange, Girish S Shroff, Gregory W Gladish, Bradley S Sabloff, Mylene T Truong

A wide variety of neoplastic and nonneoplastic conditions occur in the mediastinum. Imaging plays a central role in the evaluation of mediastinal pathologies and their mimics. Localization of a mediastinal lesion to a compartment and characterization of morphology, density/signal intensity, enhancement, and mass effect on neighboring structures can help narrow the differentials. The International Thymic Malignancy Interest Group (ITMIG) established a cross-sectional imaging-derived and anatomy-based classification system for mediastinal compartments, comprising the prevascular (anterior), visceral (middle), and paravertebral (posterior) compartments. Cross-sectional imaging is integral in the evaluation of mediastinal lesions. Computed tomography (CT) and magnetic resonance imaging (MRI) are useful to characterize mediastinal lesions detected on radiography. Advantages of CT include its widespread availability, fast acquisition time, relatively low cost, and ability to detect calcium. Advantages of MRI include the lack of radiation exposure, superior soft tissue contrast resolution to detect invasion of the mass across tissue planes, including the chest wall and diaphragm, involvement of neurovascular structures, and the potential for dynamic sequences during free-breathing or cinematic cardiac gating to assess motion of the mass relative to adjacent structures. MRI is superior to CT in the differentiation of cystic from solid lesions and in the detection of fat to differentiate thymic hyperplasia from thymic malignancy.

纵隔有各种各样的肿瘤和非肿瘤性疾病。影像学在纵隔病理及其模拟的评估中起着核心作用。将纵隔病变定位到一个腔室,并对形态学、密度/信号强度、增强和邻近结构的质量效应进行表征,有助于缩小差异。国际胸腺恶性肿瘤研究小组(ITMIG)建立了纵隔腔室的横断面成像和基于解剖学的分类系统,包括血管前(前)、内脏(中)和椎旁(后)腔室。横断成像是评估纵隔病变不可或缺的。计算机断层扫描(CT)和磁共振成像(MRI)是有用的表征纵膈病变的x线检查。CT的优点是广泛可用,采集时间快,成本相对较低,能够检测到钙。MRI的优点包括缺乏辐射暴露,优越的软组织对比度分辨率,可检测跨越组织平面(包括胸壁和隔膜)的肿块侵犯,累及神经血管结构,以及在自由呼吸或电影心脏门控期间动态序列的潜力,以评估肿块相对于邻近结构的运动。MRI在区分囊性病变和实性病变方面优于CT,在区分胸腺增生和胸腺恶性肿瘤方面优于CT。
{"title":"Multimodality imaging of mediastinal masses and mimics.","authors":"John Matthew Archer,&nbsp;Jitesh Ahuja,&nbsp;Chad D Strange,&nbsp;Girish S Shroff,&nbsp;Gregory W Gladish,&nbsp;Bradley S Sabloff,&nbsp;Mylene T Truong","doi":"10.21037/med-22-53","DOIUrl":"https://doi.org/10.21037/med-22-53","url":null,"abstract":"<p><p>A wide variety of neoplastic and nonneoplastic conditions occur in the mediastinum. Imaging plays a central role in the evaluation of mediastinal pathologies and their mimics. Localization of a mediastinal lesion to a compartment and characterization of morphology, density/signal intensity, enhancement, and mass effect on neighboring structures can help narrow the differentials. The International Thymic Malignancy Interest Group (ITMIG) established a cross-sectional imaging-derived and anatomy-based classification system for mediastinal compartments, comprising the prevascular (anterior), visceral (middle), and paravertebral (posterior) compartments. Cross-sectional imaging is integral in the evaluation of mediastinal lesions. Computed tomography (CT) and magnetic resonance imaging (MRI) are useful to characterize mediastinal lesions detected on radiography. Advantages of CT include its widespread availability, fast acquisition time, relatively low cost, and ability to detect calcium. Advantages of MRI include the lack of radiation exposure, superior soft tissue contrast resolution to detect invasion of the mass across tissue planes, including the chest wall and diaphragm, involvement of neurovascular structures, and the potential for dynamic sequences during free-breathing or cinematic cardiac gating to assess motion of the mass relative to adjacent structures. MRI is superior to CT in the differentiation of cystic from solid lesions and in the detection of fat to differentiate thymic hyperplasia from thymic malignancy.</p>","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":"7 ","pages":"27"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ae/f0/med-07-27.PMC10493620.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10295526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pyopericardium and extensive mediastinal abscess following EBUS-TBNA for mediastinal staging of NSCLC: a case report. EBUS-TBNA用于NSCLC纵隔分期的心包厚和广泛纵隔脓肿1例报告。
Pub Date : 2023-01-01 DOI: 10.21037/med-22-13
Marc Hartert, Michael Wolf, Martin Huertgen

Background: Based on the algorithm on preoperative mediastinal staging in patients with non-small cell lung cancer (NSCLC), endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is indicated in case of computed tomography (CT)-enlarged or positron emission tomography (PET)-positive mediastinal lymph nodes. It represents both a safe minimal invasive procedure with complication rates of less than 1.5% and a valid tool with a high sensitivity defining mediastinal nodal disease. However, infectious complications like mediastinitis or pyopericardium are most feared.

Case description: A 54-year-old woman was admitted to our hospital for further investigation of a suspected NSCLC of the right upper lobe. EBUS-TBNA was performed to receive both diagnosis and samples of the mediastinal lymph nodes. Two weeks after EBUS-TBNA, the patient presented with symptoms of cardiogenic/septic shock: hypotension, tachycardia, chest pain and fever. Prompt diagnosis of concomitant infectious mediastinitis and extensive pyopericardium in consequence of EBUS-TBNA was obvious. Besides systemic antibiotics, bilateral thoracoscopic interventions finally made the breakthrough. The patient could be discharged roughly three weeks after emergent re-admittance. As being finally diagnosed with NSCLC (stage IIIA squamous cell carcinoma), the patient underwent-subsequent to induction chemotherapy-a definitive sequential chemoradiotherapy. Twelve-month follow-up confirmed stable disease.

Conclusions: It is to be expected that with increasing application of EBUS-TBNA as mediastinal staging tool, the number of serious infection-related complications will rise accordingly. The efficacy of antibiotic prophylaxis after EBUS-TBNA has not yet been proved and is therefore not included in any guideline. Our case gives an impression on the severity of delayed infectious complications after EBUS-TBNA and outlines up-front surgery as primary objective to broadly debride all contagious abscess-/empyema sites. With increased use of EBUS-TBNA as mediastinal staging tool, clinicians should be aware of this rare but highly critical peri-interventional complication in order to closely monitor endangered patients.

背景:基于非小细胞肺癌(NSCLC)患者纵隔淋巴结术前分期算法,对于CT放大或PET阳性的纵隔淋巴结,建议采用支气管超声引导下经支气管针吸术(EBUS-TBNA)。它既是一种安全的微创手术,并发症发生率低于1.5%,也是一种有效的工具,具有高灵敏度,可以确定纵隔淋巴结疾病。然而,感染性并发症如纵隔炎或心包膜是最令人担心的。病例描述:一名54岁女性因疑似右上叶非小细胞肺癌入院接受进一步检查。采用EBUS-TBNA进行诊断和纵隔淋巴结标本采集。EBUS-TBNA后2周,患者出现心源性/感染性休克症状:低血压、心动过速、胸痛和发热。EBUS-TBNA对合并感染性纵隔炎和广泛心包膜的及时诊断是显而易见的。除全身性抗生素外,双侧胸腔镜干预最终取得突破。患者在紧急再次入院后大约三周可以出院。由于最终诊断为NSCLC (IIIA期鳞状细胞癌),患者在诱导化疗后接受了明确的序贯放化疗。12个月随访证实病情稳定。结论:可以预见,随着EBUS-TBNA作为纵隔分期工具的应用越来越广泛,严重感染相关并发症的数量也会相应增加。EBUS-TBNA后抗生素预防的有效性尚未得到证实,因此未列入任何指南。我们的病例显示了EBUS-TBNA后延迟感染性并发症的严重程度,并概述了前期手术作为广泛清除所有传染性脓肿/脓胸部位的主要目标。随着越来越多地使用EBUS-TBNA作为纵隔分期工具,临床医生应该意识到这种罕见但高度关键的介入期并发症,以便密切监测高危患者。
{"title":"Pyopericardium and extensive mediastinal abscess following EBUS-TBNA for mediastinal staging of NSCLC: a case report.","authors":"Marc Hartert,&nbsp;Michael Wolf,&nbsp;Martin Huertgen","doi":"10.21037/med-22-13","DOIUrl":"https://doi.org/10.21037/med-22-13","url":null,"abstract":"<p><strong>Background: </strong>Based on the algorithm on preoperative mediastinal staging in patients with non-small cell lung cancer (NSCLC), endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is indicated in case of computed tomography (CT)-enlarged or positron emission tomography (PET)-positive mediastinal lymph nodes. It represents both a safe minimal invasive procedure with complication rates of less than 1.5% and a valid tool with a high sensitivity defining mediastinal nodal disease. However, infectious complications like mediastinitis or pyopericardium are most feared.</p><p><strong>Case description: </strong>A 54-year-old woman was admitted to our hospital for further investigation of a suspected NSCLC of the right upper lobe. EBUS-TBNA was performed to receive both diagnosis and samples of the mediastinal lymph nodes. Two weeks after EBUS-TBNA, the patient presented with symptoms of cardiogenic/septic shock: hypotension, tachycardia, chest pain and fever. Prompt diagnosis of concomitant infectious mediastinitis and extensive pyopericardium in consequence of EBUS-TBNA was obvious. Besides systemic antibiotics, bilateral thoracoscopic interventions finally made the breakthrough. The patient could be discharged roughly three weeks after emergent re-admittance. As being finally diagnosed with NSCLC (stage IIIA squamous cell carcinoma), the patient underwent-subsequent to induction chemotherapy-a definitive sequential chemoradiotherapy. Twelve-month follow-up confirmed stable disease.</p><p><strong>Conclusions: </strong>It is to be expected that with increasing application of EBUS-TBNA as mediastinal staging tool, the number of serious infection-related complications will rise accordingly. The efficacy of antibiotic prophylaxis after EBUS-TBNA has not yet been proved and is therefore not included in any guideline. Our case gives an impression on the severity of delayed infectious complications after EBUS-TBNA and outlines up-front surgery as primary objective to broadly debride all contagious abscess-/empyema sites. With increased use of EBUS-TBNA as mediastinal staging tool, clinicians should be aware of this rare but highly critical peri-interventional complication in order to closely monitor endangered patients.</p>","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":"7 ","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d3/48/med-07-4.PMC10011863.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9138170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Esophageal duplication cysts: a clinical practice review. 食管重复囊肿:临床实践回顾。
Pub Date : 2023-01-01 DOI: 10.21037/med-22-33
Jessica E Wahi, Fernando M Safdie

Esophageal duplication represents one of the most common types of bronchopulmonary foregut malformations. These rare congenital anomalies occur secondary to embryological aberrations between the 4th and 8th weeks of gestation. In order to be classified as an esophageal cyst a mediastinal cyst must have a close proximity with the esophagus, be lined by alimentary (squamous epithelium) or tracheobronchial mucosa and covered by two smooth muscle layers. These rare anomalies are often asymptomatic during adulthood. However, they can cause symptoms in early childhood, generally during the first 2 years of life. Variations in location, size, presence or absence of heterotopic mucosa, will dictate the clinical presentation. Dysphagia, food impaction, persistent cough and chest pain are common clinical presentations. Imaging studies including esophagram, computed tomography (CT) and magnetic resonance imaging (MRI) can provide key findings to reach the diagnosis. Nonetheless, endoscopic evaluation, particularly endoscopic ultrasound (EUS) is the most valuable tool to determine whether this lesion is cystic versus solid and or if there are abnormal mucosal findings. Needle biopsies are controversial but can help with drainage and to rule out malignant transformation. Therapeutic options include endoluminal drainage. However, more definitive therapies include surgical excision. Open and minimally invasive (laparoscopic and thoracoscopic) techniques have been demonstrated to be safe and effective at completely removing these lesions. Recently, robotic-assisted resections have gained more attention with case reports and series reporting excellent outcomes.

食管重复是支气管肺前肠畸形最常见的类型之一。这些罕见的先天性异常发生继发于胚胎学异常在妊娠4和8周之间。要归类为食道囊肿,纵隔囊肿必须靠近食道,内衬有消化道粘膜(鳞状上皮)或气管支气管粘膜,并被两层平滑肌覆盖。这些罕见的异常在成年期通常无症状。然而,它们可以在儿童早期引起症状,通常在生命的头两年。位置、大小、有无异位粘膜的变化将决定临床表现。吞咽困难,食物嵌塞,持续咳嗽和胸痛是常见的临床表现。影像学检查包括食管造影,计算机断层扫描(CT)和磁共振成像(MRI)可以提供关键的发现,以达到诊断。尽管如此,内镜评估,特别是内镜超声(EUS)是确定该病变是囊性还是实性以及是否有异常粘膜发现的最有价值的工具。针活检是有争议的,但可以帮助引流和排除恶性转化。治疗方案包括肠内引流。然而,更明确的治疗方法包括手术切除。开放和微创(腹腔镜和胸腔镜)技术已被证明在完全切除这些病变方面是安全有效的。最近,机器人辅助切除获得了更多的关注,病例报告和系列报道了良好的结果。
{"title":"Esophageal duplication cysts: a clinical practice review.","authors":"Jessica E Wahi,&nbsp;Fernando M Safdie","doi":"10.21037/med-22-33","DOIUrl":"https://doi.org/10.21037/med-22-33","url":null,"abstract":"<p><p>Esophageal duplication represents one of the most common types of bronchopulmonary foregut malformations. These rare congenital anomalies occur secondary to embryological aberrations between the 4th and 8th weeks of gestation. In order to be classified as an esophageal cyst a mediastinal cyst must have a close proximity with the esophagus, be lined by alimentary (squamous epithelium) or tracheobronchial mucosa and covered by two smooth muscle layers. These rare anomalies are often asymptomatic during adulthood. However, they can cause symptoms in early childhood, generally during the first 2 years of life. Variations in location, size, presence or absence of heterotopic mucosa, will dictate the clinical presentation. Dysphagia, food impaction, persistent cough and chest pain are common clinical presentations. Imaging studies including esophagram, computed tomography (CT) and magnetic resonance imaging (MRI) can provide key findings to reach the diagnosis. Nonetheless, endoscopic evaluation, particularly endoscopic ultrasound (EUS) is the most valuable tool to determine whether this lesion is cystic versus solid and or if there are abnormal mucosal findings. Needle biopsies are controversial but can help with drainage and to rule out malignant transformation. Therapeutic options include endoluminal drainage. However, more definitive therapies include surgical excision. Open and minimally invasive (laparoscopic and thoracoscopic) techniques have been demonstrated to be safe and effective at completely removing these lesions. Recently, robotic-assisted resections have gained more attention with case reports and series reporting excellent outcomes.</p>","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":"7 ","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/89/6a/med-07-1.PMC10011867.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9131146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
The European Reference Network: the keystone for the management of rare thoracic cancers. 欧洲参考网络:罕见胸癌管理的基石。
Pub Date : 2023-01-01 DOI: 10.21037/med-22-10
Rocco Morra, Antonio D'Ambrosio, Erica Pietroluongo, Pietro De Placido, Liliana Montella, Vitoantonio Del Deo, Marianna Tortora, Sabino De Placido, Giovannella Palmieri, Mario Giuliano
© Mediastinum. All rights reserved. Mediastinum 2023;7:7 | https://dx.doi.org/10.21037/med-22-10 Rare tumors are a heterogeneous group of malignancies, which show an incidence rate of <6 per 100,000 people per year, according to the definition of Surveillance of Rare Cancers in Europe (RARECARE) (1). Overall, the estimated incidence of all rare tumors in Europe accounts for 24% of all cancers, with 5-year relative survival for all rare cancers of 48.5% (2). Indeed, rare thoracic tumors include many entities: epithelial tumors of the trachea, rare epithelial tumors of the lung, epithelial tumors of the thymus, malignant pleural and pericardial mesothelioma, mediastinal germ cell tumors and mesenchymal tumors (Table 1) (1,3-5). The incidence of these tumors in Europe is the highest in patients aged 65 years and older, with a crude rate of 1.4 per million per year for the epithelial tumor of the trachea, 1.7 per million per year for thymic epithelial tumors, among which malignant thymomas are the most common, and 16 per million per year for the malignant mesothelioma of pleura and pericardium. The 5-years relative survival rate is 14% for the epithelial tumors of the trachea, 65.6% for thymic epithelial tumors, and 5.4% for malignant mesothelioma (5). Detailed data on incidence, prevalence and survival of several types of rare thoracic tumors included in Table 1 were reported in a study of the RARECARE working group, using a large patient database (5). These malignancies present an intrinsic complexity in clinical management, both in the initial diagnostic phase, as well as in the treatment choice, due to scarcity of clinical practice guidelines and also to the lack of randomized clinical trials, which substantially limit treatment options. Moreover, to reduce the diagnostic delay and to improve the appropriateness of treatment choice, clinical centers with adequate patient volumes and expertise should be homogeneously accessible in different geographical areas, also to reduce healthcare migration (3,6,7). Notably, the clinical complexity of rare thoracic tumors systematically requires multidisciplinary team discussion to reach the correct diagnosis and offer the best treatment. In 2008, the European Commission launched the RARECARE project. This is a population-based cancer registry aiming at defining incidence, prevalence and long-term outcome of rare cancers. This project allows to study the epidemiology of these cancers in a large and heterogeneous population (8,9). The results of RARECARE registry led to a second project (RARECAREnet), which updated and enlarged the available information on rare cancers in Europe (10). In addition, the Joint Action on Rare Cancers (JARC) launched in 2016, is another major European initiative, in which 34 partners from different countries belonging to the European Community are involved. This project, coordinated by the National Cancer Institute of Milan (INT), seeks to improve the epidemiological knowledge of r
{"title":"The European Reference Network: the keystone for the management of rare thoracic cancers.","authors":"Rocco Morra,&nbsp;Antonio D'Ambrosio,&nbsp;Erica Pietroluongo,&nbsp;Pietro De Placido,&nbsp;Liliana Montella,&nbsp;Vitoantonio Del Deo,&nbsp;Marianna Tortora,&nbsp;Sabino De Placido,&nbsp;Giovannella Palmieri,&nbsp;Mario Giuliano","doi":"10.21037/med-22-10","DOIUrl":"https://doi.org/10.21037/med-22-10","url":null,"abstract":"© Mediastinum. All rights reserved. Mediastinum 2023;7:7 | https://dx.doi.org/10.21037/med-22-10 Rare tumors are a heterogeneous group of malignancies, which show an incidence rate of <6 per 100,000 people per year, according to the definition of Surveillance of Rare Cancers in Europe (RARECARE) (1). Overall, the estimated incidence of all rare tumors in Europe accounts for 24% of all cancers, with 5-year relative survival for all rare cancers of 48.5% (2). Indeed, rare thoracic tumors include many entities: epithelial tumors of the trachea, rare epithelial tumors of the lung, epithelial tumors of the thymus, malignant pleural and pericardial mesothelioma, mediastinal germ cell tumors and mesenchymal tumors (Table 1) (1,3-5). The incidence of these tumors in Europe is the highest in patients aged 65 years and older, with a crude rate of 1.4 per million per year for the epithelial tumor of the trachea, 1.7 per million per year for thymic epithelial tumors, among which malignant thymomas are the most common, and 16 per million per year for the malignant mesothelioma of pleura and pericardium. The 5-years relative survival rate is 14% for the epithelial tumors of the trachea, 65.6% for thymic epithelial tumors, and 5.4% for malignant mesothelioma (5). Detailed data on incidence, prevalence and survival of several types of rare thoracic tumors included in Table 1 were reported in a study of the RARECARE working group, using a large patient database (5). These malignancies present an intrinsic complexity in clinical management, both in the initial diagnostic phase, as well as in the treatment choice, due to scarcity of clinical practice guidelines and also to the lack of randomized clinical trials, which substantially limit treatment options. Moreover, to reduce the diagnostic delay and to improve the appropriateness of treatment choice, clinical centers with adequate patient volumes and expertise should be homogeneously accessible in different geographical areas, also to reduce healthcare migration (3,6,7). Notably, the clinical complexity of rare thoracic tumors systematically requires multidisciplinary team discussion to reach the correct diagnosis and offer the best treatment. In 2008, the European Commission launched the RARECARE project. This is a population-based cancer registry aiming at defining incidence, prevalence and long-term outcome of rare cancers. This project allows to study the epidemiology of these cancers in a large and heterogeneous population (8,9). The results of RARECARE registry led to a second project (RARECAREnet), which updated and enlarged the available information on rare cancers in Europe (10). In addition, the Joint Action on Rare Cancers (JARC) launched in 2016, is another major European initiative, in which 34 partners from different countries belonging to the European Community are involved. This project, coordinated by the National Cancer Institute of Milan (INT), seeks to improve the epidemiological knowledge of r","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":"7 ","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/36/be/med-07-7.PMC10011864.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9138172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intralesional microbleeding in resected thymic cysts indeterminate on imaging. 切除胸腺囊肿的病灶内微出血在影像学上不确定。
Pub Date : 2023-01-01 DOI: 10.21037/med-22-42
Julian A Villalba, Adina Haramati, Michelle Garlin, Fabiola Reyes, Cameron D Wright, Abner Louissaint, Jeanne B Ackman

Background: The propensity of thymic cysts to mimic solid thymic epithelial tumors (TETs) on computed tomography (CT), on account of attenuation values greater than water and thickened or calcified walls, can lead to non-therapeutic thymectomy. These lesions can fluctuate in volume, CT attenuation, and magnetic resonance imaging (MRI) signal over time. We hypothesized that spontaneous hemorrhage and resorption may contribute to their variable appearance over time.

Methods: Completely excised thymic cysts were identified retrospectively over a 20-year period by their pathologic diagnosis. Cysts were excluded if they did not have available presurgical imaging, were not prevascular, were located within or contained an enhancing mass by imaging, or were of non-thymic origin upon microscopic review. Histopathological analysis of all available resected thymic cyst material and radiologic analysis of the cysts on pre-operative imaging were performed.

Results: Upon application of exclusion criteria, we identified 18 thymic cysts from the initial 85 mediastinal cystic specimens. Most cysts were unilocular (11/15, 73%), showed turbid-to-semisolid, hemorrhagic fluid (10/12, 83%) and showed histopathological findings suggestive of intralesional microbleeding (14/18, 78%), remodeling (8/18, 44%), pathological wound healing/scarring of the capsule (16/18, 89%), and fat necrosis in the surrounding thymic tissue (12/18, 67%). On CT, 6/17 (35%) cysts demonstrated wall calcification. Sixty-five percent (11/17) had attenuation values ≥20 Hounsfield units (HU). Two of the 4 cysts imaged by MRI were T1-isointense, one was mixed hyper- and isointense, and one T1-hypointense to muscle, with iso- and hyperintensity indicating hemorrhagic or proteinaceous content. Twenty-five percent (1/4) of cyst walls imaged by MRI were T1/T2-hypointense, indicating presence of calcification, hemosiderin, and/or fibrosis.

Conclusions: Resected thymic cysts in this cohort often showed features suggestive of intralesional microbleeding, inflammation, and fibrosis, which may explain their appearance and behavior over time on CT and MRI.

背景:由于胸腺囊肿的衰减值大于水,壁增厚或钙化,在计算机断层扫描(CT)上,胸腺囊肿倾向于模拟胸腺实体上皮瘤(TETs),可导致非治疗性胸腺切除术。这些病变在体积、CT衰减和磁共振成像(MRI)信号上随时间波动。我们假设自发性出血和吸收可能是导致其随时间变化的原因。方法:通过20年的病理诊断,对完全切除的胸腺囊肿进行回顾性分析。如果囊肿没有术前显像,没有血管前显像,位于或包含增强肿块,或显微镜检查非胸腺起源,则排除囊肿。对所有切除的胸腺囊肿材料进行组织病理学分析,并对囊肿术前影像学进行放射学分析。结果:根据排除标准,我们从最初的85例纵隔囊肿标本中鉴定出18例胸腺囊肿。大多数囊肿为单眼(11/15,73%),呈浑浊至半固体状,出血性液体(10/12,83%),组织病理学表现提示病灶内微出血(14/18,78%),重塑(8/18,44%),病理性伤口愈合/包膜瘢痕(16/18,89%),胸腺周围组织脂肪坏死(12/18,67%)。CT上,6/17(35%)囊肿显示壁钙化。65%(11/17)的衰减值≥20 Hounsfield单位(HU)。MRI成像的4个囊肿中有2个为t1等强度,1个为混合高、等强度,1个为t1低强度到肌肉,等强度和高强度提示出血或蛋白质含量。25%(1/4)的囊肿壁MRI成像为T1/ t2低信号,表明存在钙化、含铁血黄素和/或纤维化。结论:本队列中切除的胸腺囊肿通常表现为病灶内微出血、炎症和纤维化的特征,这可以解释其在CT和MRI上随时间变化的外观和行为。
{"title":"Intralesional microbleeding in resected thymic cysts indeterminate on imaging.","authors":"Julian A Villalba,&nbsp;Adina Haramati,&nbsp;Michelle Garlin,&nbsp;Fabiola Reyes,&nbsp;Cameron D Wright,&nbsp;Abner Louissaint,&nbsp;Jeanne B Ackman","doi":"10.21037/med-22-42","DOIUrl":"https://doi.org/10.21037/med-22-42","url":null,"abstract":"<p><strong>Background: </strong>The propensity of thymic cysts to mimic solid thymic epithelial tumors (TETs) on computed tomography (CT), on account of attenuation values greater than water and thickened or calcified walls, can lead to non-therapeutic thymectomy. These lesions can fluctuate in volume, CT attenuation, and magnetic resonance imaging (MRI) signal over time. We hypothesized that spontaneous hemorrhage and resorption may contribute to their variable appearance over time.</p><p><strong>Methods: </strong>Completely excised thymic cysts were identified retrospectively over a 20-year period by their pathologic diagnosis. Cysts were excluded if they did not have available presurgical imaging, were not prevascular, were located within or contained an enhancing mass by imaging, or were of non-thymic origin upon microscopic review. Histopathological analysis of all available resected thymic cyst material and radiologic analysis of the cysts on pre-operative imaging were performed.</p><p><strong>Results: </strong>Upon application of exclusion criteria, we identified 18 thymic cysts from the initial 85 mediastinal cystic specimens. Most cysts were unilocular (11/15, 73%), showed turbid-to-semisolid, hemorrhagic fluid (10/12, 83%) and showed histopathological findings suggestive of intralesional microbleeding (14/18, 78%), remodeling (8/18, 44%), pathological wound healing/scarring of the capsule (16/18, 89%), and fat necrosis in the surrounding thymic tissue (12/18, 67%). On CT, 6/17 (35%) cysts demonstrated wall calcification. Sixty-five percent (11/17) had attenuation values ≥20 Hounsfield units (HU). Two of the 4 cysts imaged by MRI were T1-isointense, one was mixed hyper- and isointense, and one T1-hypointense to muscle, with iso- and hyperintensity indicating hemorrhagic or proteinaceous content. Twenty-five percent (1/4) of cyst walls imaged by MRI were T1/T2-hypointense, indicating presence of calcification, hemosiderin, and/or fibrosis.</p><p><strong>Conclusions: </strong>Resected thymic cysts in this cohort often showed features suggestive of intralesional microbleeding, inflammation, and fibrosis, which may explain their appearance and behavior over time on CT and MRI.</p>","PeriodicalId":74139,"journal":{"name":"Mediastinum (Hong Kong, China)","volume":"7 ","pages":"13"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/01/fd/med-07-13.PMC10226889.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9620835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Mediastinum (Hong Kong, China)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1